Expression of PDGFRb on tumor pericytes has allowed targeting of pericytes in cancer therapy, and preclinical analyses have indicated that combined anti-VEGF and anti-PDGF therapy may be beneficial (60). The gene discussed is PDGFRB; the disease is cancer.